You can have your damaged heart valve replaced minimally without opening the chest

Many patients with heart valve disease present with a critical narrowing of the aortic valve, the main valve responsible for pumping oxygenated blood from the heart to the aorta and the rest of the body. This narrowing severely restricts blood flow, often due to the buildup of calcium deposits on the valve leaflets. As a result, the heart must work harder to pump blood.

The excessive pressure required to pump blood through the narrowed valve places further strain on the heart. This causes symptoms such as shortness of breath and severe fatigue, a condition known as aortic stenosis. In younger patients, the cause is typically rheumatic fever; in older patients, it is most often progressive age-related valve degeneration.

Once symptomatic, the definitive treatment is to replace the diseased valve. Aortic stenosis is a progressive disease; if left untreated, up to half of patients will die within six months of symptom onset. Unfortunately, many patients are diagnosed at an advanced stage, when they are already too ill or frail to safely undergo the required open-heart surgery.

Also read: Hope for millions of patients as scientists discover how human heart can finally repair itself

Aortic valve disease —a malfunction of the heart's aortic valve—poses significant health risks, particularly for the aging population where it is most prevalent. This condition manifests in two primary forms: aortic stenosis (narrowing of the valve) or aortic regurgitation (leaking of the valve).

For decades, surgical aortic valve replacement (SAVR) has been the global standard of care. However, the advent of transcatheter aortic valve implantation (TAVI) has transformed the treatment paradigm. In many countries, TAVI is now considered a first-line alternative to SAVR for severe aortic stenosis. This evolution raises a critical question for Africa, a continent with diverse and often resource-constrained healthcare systems: Is now the prime time for TAVI?

TAVI is a minimally invasive procedure in which a new valve is delivered to the heart via a catheter; a small tube typically inserted through a large blood vessel in the groin. The prosthetic valve is guided through the catheter and positioned inside the diseased aortic valve, where it begins functioning immediately.

High risk

TAVI has revolutionised the treatment of severe aortic stenosis, especially for patients considered at high or intermediate risk for traditional open-heart surgery. This approach significantly reduces recovery time and procedural complications, making it a preferred option for elderly patients and those with other medical problems.

While SAVR, the historical gold standard, requires opening the chest to access the heart, TAVI employs a minimally invasive approach. The TAVI procedure accesses the heart via a major blood vessel—typically in the groin—to deliver and implant a new valve in the aortic position.

The TAVI procedure itself typically takes about an hour and is performed under local anesthesia, often with conscious sedation, eliminating the need for general anesthesia required by SAVR. Most patients are discharged from the hospital the following day, with an average recovery time of just one to three days. The procedure boasts a high success rate of up to 95 per cent.

In high-income countries, TAVI is now an established, guideline-directed treatment with expanding indications and consistently improving outcomes. Technological advancements and a robust evidence base have made the procedure accessible to an increasingly broad patient population.

The situation in Africa, however, presents a distinct landscape of challenges and opportunities. Access to this transformative treatment is hindered by significant hurdles, including severe resource constraints. Many countries face shortages of specialised equipment, trained personnel, and dedicated funding. Consequently, despite its enormous clinical potential, the cost of TAVI remains prohibitively high for the average African citizen.

The true burden of aortic valve disease in Africa remains difficult to quantify due to a critical lack of population-based epidemiological studies. A significant additional challenge is infrastructure. The specialised equipment required for TAVI, including hybrid cardiac catheterisation labs and advanced post-operative care facilities, is concentrated in a limited number of high-end hospitals and is not uniformly available across the continent. This scarcity, compounded by a shortage of adequately trained personnel, confines the procedure's availability to a few major urban centers.

Also read: Crippling costs and delays: 36 per cent of Kenyan children die waiting for heart surgery

Rheumatic heart disease remains the leading cause of valvular heart disease, including aortic valve pathologies. Concurrently, degenerative aortic stenosis is rising, driven by increasing life expectancy and changing lifestyle patterns. This dual disease burden necessitates a diverse and adaptable treatment approach. Encouragingly, contemporary studies indicate that TAVI can be a safe and effective intervention for aortic stenosis, even when the underlying cause is rheumatic heart disease.

As the healthcare landscape in Africa evolves, the potential for TAVI to become a standard treatment for aortic valve disease grows increasingly tangible. 
The journey presents undeniable challenges, yet the benefits of TAVI—reduced invasiveness, lower complication rates, quicker recovery, and suitability for high-risk patients—remain compelling.

TAVI has already revolutionised the treatment of aortic stenosis across much of the world. While the question of whether now is the prime time for TAVI in Africa involves multiple confounding factors, the progress achieved and the growing recognition of the procedure's value suggest it is indeed on the horizon for the continent.

As the continent navigates the complexities of modern healthcare delivery, TAVI represents a revolutionary frontier in the management of aortic valve disease. To realise its potential, it is crucial for health policymakers and frontline healthcare personnel to recognise the profound benefits of this innovation and take decisive steps to expand TAVI’s accessibility across Africa.

Dr Amendezo and Dr Jeilan are consultant interventional cardiologists, while Dr Ochola is a cardiology fellow at Aga Khan University Hospital, Nairobi